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1. Introduction 
Parkinson’s disease (PD) is a common neurological movement disorder that is characterized 
by bradykinesia, muscle rigidity and tremor due to progressive loss of dopaminergic 
nigrostriatal neurons. Currently, pharmacological treatment with levodopa (LD), the 
precursor of dopamine (DA), or other DA replacement therapies, such as synthetic DA 
agonists, are used to ameliorate parkinsonian symptoms. Although these treatments are 
effective at alleviating parkinsonism during the early stages of the disease, most advanced 
PD patients develop disabling, motor complications known as drug-induced dyskinesias. In 
this chapter, we define drug-induced dyskinesias as abnormal, excessive involuntary 
movements that occur with oral, pharmacological anti-parkinsonian medications for PD. 
One classic example is LD-induced dyskinesias. These disabling movements limit the 
effectiveness of pharmacological treatments.  
The aim of this chapter is to introduce the phenomenology of drug-induced dyskinesias and 
evaluate the current theories for drug-induced dyskinesias, covering recent studies that 
identify the underlying pathophysiological changes on the biochemical/molecular 
(receptors, enzymes, and neurotransmitter systems), cellular (basal ganglia connections), 
electrophysiological (basal ganglia neuronal activity) and behavioral level that have been 
proposed to influence the development of drug-induced dyskinesias. We will also describe 
various treatment strategies currently utilized for drug-induced dyskinesias including 
adjunct pharmacological therapies and functional neurosurgery, most of which are currently 
limited in effectively diminishing drug-induced dyskinesias or unattainable for many 
patients. Because of the disabling nature of drug-induced dyskinesias, understanding the 
factors that contribute to the onset of drug-induced dyskinesias in PD will allow for the 
development of improved and novel treatment strategies that prevent or mitigate drug-
induced dyskinesias without diminution of anti-parkinsonian effects. 
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2. Behavioral characteristics of drug-induced dyskinesias 
2.1 Drug-induced dyskinesias in Parkinson’s disease 
Peak-dose dyskinesias are the most common form of dyskinesias and occur in 75% to 80% of 
the patients experiencing dyskinesias (Zesiewicz et al., 2007). The major risk factor has been 
considered to be severity of the disease. Peak-dose dyskinesias are due to a high dose of LD 
and represent an overdosed state. The plasma levels of LD are high and there is presumably 
excess striatal DA. Chorea is the most common form of involuntary movement in these 
cases. However, in later stages, dystonia can also occur. Chorea is more prominent in the 
head, trunk and upper limbs (Thanvi et al., 2007). Reducing the individual dose of anti-
parkinsonian medication ameliorates the dyskinesias but can cause deterioration of 
parkinsonism. Hence these patients typically need more frequent dosing of anti-
parkinsonian medication. Sustained-release LD formulations may prolong the duration of 
dyskinesia. 
Diphasic dyskinesias develop when plasma levels are rising or falling but not with peak 
levels. These dyskinesias predominantly occur in the lower limbs and tend to be dystonic or 
choreiform. Treatment of diphasic dyskinesias is more difficult than peak-dose dyskinesias. 
Higher doses of LD can induce peak-dose dyskinesias and other adverse effects, while lower 
doses cause worsening of parkinsonism. The use of DA agonists with a longer duration of 
action and LD as supplementary drug is the most effective approach. 
Off-period dystonia occurs when the plasma levels of DA are low, particularly in the early 
morning. It can be precipitated by anxiety or attempts to walk. It is characterized by painful 
spasms of the foot on the more affected side. It is treated by preventing the “offs”. This can be 
achieved by use of DA agonists or sustained release LD formulations (Zesiewicz et al., 2007). 
2.2 Preclinical animal models of drug-induced dyskinesias 
2.2.1 Rodent models 
Unilateral injection of the neurotoxin 6-hydroxydopamine (6-OHDA) into the medial 
forebrain bundle (MFB) induces selective loss of nigrostriatal neurons (Ungerstedt & 
Arbuthnott, 1970) in the rat. This causes extensive loss of nigrostriatal neurons unilaterally 
(>95% loss), and significant loss of DA. This leads to a hemiparkinsonian rat model of PD 
that exhibits motor deficits in the forelimb contralateral to lesion. Administration of 
pharmacological DA replacement therapies such as LD or DA agonists induces abnormal 
involuntary, dyskinetic movements and contralateral rotational behavior. These abnormal 
involuntary movements are separated into orolingual dyskinesias (rapid protrusion of the 
tongue and chewing movements), truncal and neck dystonic posturing in the direction 
contralateral to lesion and hyperkinetic/dystonic posturing of the forelimb contralateral to 
lesion (Cenci et al., 1998; Steece-Collier et al., 2003; Lieu et al., 2010). Similar to the 
hemiparkinsonian rat, 6-OHDA can be injected into the MFB or striatum to create 
hemiparkinsonian dyskinetic mice (Lundblad et al., 2004; Pavon et al., 2006). In mice, 
knockout of the PitX3 gene prevents the development of nigrostriatal neurons. LD exposure 
induces dyskinesias in these animals in the form of hyperkinetic movements of the 
forelimbs and hindlimbs (Ding et al., 2011).  
2.2.2 Primate models  
Primates have played an important role in understanding the pathophysiological basis of 
drug-induced dyskinesias and in preclinical experimental therapeutics targeted at 
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diminishing or preventing drug-induced dyskinesias. Investigators have utilized various 
species to model drug-induced dyskinesias that include squirrel monkeys, common 
marmosets, macaques and vervet nonhuman primates (Boyce et al., 1990; Pearce et al., 1995; 
Heimer et al., 2006; Liang et al., 2008). Exposure to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) leads to selective loss of dopaminergic nigrostriatal neurons, 
and is used in primates to induce parkinsonism. LD and other pharmacological DA 
replacement therapy induces hyperkinetic, abnormal involuntary movements 
(choreoathetosis, violent jerks, flailing of the limbs), dystonic, abnormal posturing in the 
extremities and trunk, and orolingual dyskinesias (purposeless protrusion of the tongue). 
This animal model displays dyskinesias more clinically similar to drug-induced dyskinesias 
in PD when compared to the parkinsonian rodent. 
The extent of nigrostriatal damage necessary to induce dyskinesias in animal models has 
demonstrated varying results. In rats and mice, development of dyskinesias is typically after 
extensive loss of nigrostriatal neurons via MFB lesion, typically upward to 95% loss of 
dopaminergic neurons when compared to the unlesioned side. Single striatal injection of 6-
OHDA as described previously (Sauer & Oertel, 1994) induces a partial lesion with 
approximately 50% degeneration. These rats do not develop dyskinesias with LD exposure. 
However, higher doses of 6-OHDA and multiple striatal injection sites can lead to extensive 
degeneration where such animals develop dyskinesias similar to the MFB-lesioned rat 
(Winkler et al., 2002). In the primate, some have demonstrated that normal monkeys 
without MPTP exposure or monkeys with minor nigrostriatal degeneration develop 
dyskinesias, whereas other investigators argue the necessity that extensive nigrostriatal 
damage bilaterally is essential for the development of dyskinesias (Kurlan et al., 1991; 
Pearce et al., 2001; Togasaki et al., 2001; Heimer et al., 2006; Liang et al., 2008). We have 
recently shown that macaque rhesus monkeys that are clinically hemiparkinsonian by 
intracarotid MPTP do not develop dyskinesias with chronic LD treatment (Lieu et al., 2011), 
indicating that bilateral parkinsonian rhesus monkey is a more suitable model for drug-
induced dyskinesias in this species. We hypothesize that one mechanism by which 
hemiparkinsonian rhesus monkeys do not develop dyskinesias is by interhemispheric 
inhibition. This may be through the small percentage of nigrostriatal neurons from the 
contralateral hemisphere innervating the denervated striatum. In the hemiparkinsonian rat, 
our group has shown that there is a loss of interhemispheric nigrostriatal neurons in the 
hemiparkinsonian dyskinetic rat. However, interhemispheric nigrostriatal neurons are 
retained in normal and partial-lesioned non-dyskinetic rats (Lieu et al., 2009). This suggests 
that loss of interhemispheric nigrostriatal neurons may play a role in the development of 
drug-induced dyskinesias.  
3. Differential diagnosis of dyskinesias 
Drug-induced dyskinesias need to be differentiated from other hyperkinetic disorders in 
patients. They are as follows: 
3.1 Tremor  
In contrast to drug-induced dyskinesias which are involuntary, continual, abrupt, brief and 
irregular, tremors are oscillatory, rhythmic and regular and tend to affect the more distal 
parts of the upper extremities. Peak-dose dyskinesias, by definition, will appear only after 
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administration of anti-PD medications (typically 60-90 min) while tremor in PD will 
frequently mitigate upon administration of anti-PD medication. Rarely, diphasic dyskinesias 
may have to be distinguished from lower extremity tremor. Diphasic dyskinesias and 
tremor are both seen when anti-PD medication levels are low. However, on administration 
of anti-PD medications, diphasic dyskinesias tend to disappear sooner and abruptly as 
compared to parkinsonian tremor, which will mitigate slowly.  
3.2 Huntington’s disease  
Chorea is a frequent manifestation of Huntington’s disease. However, Huntington’s chorea 
is easily distinguished by the family history, absence of temporal relation to dosing of anti-
PD medications and by presence of several other typical findings in Huntington’s disease 
that separates this entity from PD. This issue is more complicated in juvenile Huntington’s 
disease. In this case, typically the patient is parkinsonian (Roos, 2010), does not exhibit 
chorea and is often treated with anti-PD medications. In this scenario, if the patient develops 
choreiform movements, they need to be distinguished from drug-induced dyskinesias as 
opposed to natural occurrence due to progression of Huntington’s disease. Following points 
may be used to make this distinction: 
a. Drug-induced dyskinesias have a temporal course to timing of anti-PD medications 
while chorea occurring in Huntington’s disease is random and has no temporal course. 
b. Juvenile Huntington’s disease is a more severe form and invariably the patient will 
have more symptoms in other neurological domains beyond simple parkinsonism 
(dementia, ataxia, etc.) 
A third scenario is when an adult Huntington’s disease patient is treated with anti-
dopaminergic medications (e.g. Haloperidol). This drug can produce tardive dyskinesias 
which need to be distinguished from drug-induced dyskinesias. 
3.3 Tics and stereotypies  
Tics are abrupt, brief, repetitive and stereotyped movements which vary in intensity and are 
repeated at irregular intervals (Jankovic, 2009). Patients usually have a generalized urge 
preceding the actual movement or local discomfort in the region of the body where the tic 
appears. Tics can be voluntarily suppressed but these result in mounting inner tension 
leading to a rebound of tics. Tics can also persist during sleep. Stereotypies are involuntary, 
patterned, repetitive, continuous, coordinated, ritualistic movements or utterances. Unlike 
tics, stereotypies are not preceded by an urge and usually occur during periods of stress, 
excitement or when engrossed. They can be ceased by distraction or initiation of a new 
activity.  
Tics and stereotypies can be differentiated from dystonia by the absence of worsening on 
attempted movements. Tics and stereotypies can be differentiated from drug-induced 
dyskinesias which are choreiform. Also, drug-induced dyskinesias cannot be voluntarily 
suppressed. 
3.4 Tardive dyskinesias 
These are involuntary movements that are seen as a complication of long-term DA receptor 
antagonist therapy and present with rapid, repetitive, stereotypic movements involving 
oral, buccal and lingual areas. In cases where the patient is currently on DA receptor 
antagonists and exhibits signs of parkinsonism and oro-bucco-lingual involuntary 
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movements, it is easy to make the distinction between tardive dyskinesias and drug-induced 
dyskinesias. However, in very rare cases where the patient has been previously treated with 
one or more DA receptor antagonists for a short period but such information is not available 
at the time of clinical presentation, it becomes essential to differentiate between drug-
induced dyskinesias and tardive dyskinesias. In such cases, the predominant oro-bucco-
lingual involvement, lack of limb and trunk involvement and the absence of improvement 
on withdrawal of drugs help to differentiate tardive dyskinesias from drug-induced 
dyskinesias. 
3.5 Myoclonus 
Myoclonus is a sequence of repeated, often nonrhythmic, brief shock-like jerks due to 
sudden involuntary contraction or relaxation of one or more muscles. Myoclonus can be 
differentiated from dystonia by the lack of distinctive postures. Rhythmic myoclonus can be 
distinguished from chorea occurring in drug-induced dyskinesias by the predictable timing 
of movements. Asynchronous multifocal myoclonus is more difficult to distinguish but can 
be done so due to the simpler, shock-like movements of myoclonus compared to the more 
complex, randomly distributed movements in chorea.  
4. Physiology of drug-induced dyskinesias 
4.1 Functional models of the basal ganglia 
Our current understanding of the functional connectivity for PD is based on the classic rate 
model of the “direct” and “indirect” pathways of the basal ganglia motor loop (Albin et al., 
1989; Alexander et al., 1990; DeLong, 1990). In this model, the dopaminergic nigrostriatal 
pathway modulates the activity of two separate pathways in the striatum (STR) (DA D1-
receptor mediated “direct” and DA D2-receptor mediated “indirect” pathways). With 
subsequent loss of DA due to nigrostriatal degeneration (neurons originating from 
substantia nigra pars compacta (SNC) and terminating in the STR) (Fig. 1A), the activity of 
the motor loops is altered, leading to parkinsonism. In the parkinsonian “direct” pathway, γ-
Aminobutyric acid (GABA)-ergic striatal input to the globus pallidus interna/substantia 
nigra reticulata (GPI/SNR) is reduced, leading to a disinhibition and overactivity of the 
GABAergic GPI and SNR. In the parkinsonian “indirect” pathway, there is an increase in 
GABAergic striatal neuron activity to the globus pallidus externa (GPE) leading to inhibition 
of the GABAergic GPE. This leads to disinhibition of the glutamatergic subthalamic nucleus 
(STN) and overactivity of this nucleus. This pathway also causes increased activity of the 
GPI and SNR. Taken together, in the parkinsonian state, both the “direct” and “indirect” 
pathways lead to an excessive inhibition of the motor thalamus (THAL) and subsequently 
the motor cortex (CTX). 
Based on this model, DA replacement therapy should result in balanced activity of the 
“direct” and “indirect” pathways (Fig. 1B). However, our group as well as other 
investigators has demonstrated that with oral pharmacological DA replacement treatment, 
various basal ganglia nuclei activity do not become “balanced” as the classic rate model 
would suggest (Heimer et al., 2002; Heimer et al., 2006; Gilmour et al., 2011). 
The classic model described above would also predict that drug-induced dyskinesias would 
be accompanied by increased thalamocortical activity, reduced inhibitory output from 
GPI/SNR to the THAL, and therefore reduced STN glutamatergic output in the “indirect” 
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pathway and increased striatal output in the “direct” pathway (Fig. 1C). While some studies 
have supported this hypothesis, others have argued against it utilizing lesioning and 
electrophysiological studies of various basal ganglia nuclei (Bergman et al., 1990; Hamada & 
DeLong, 1992; Papa et al., 1999; Baron et al., 2000). Therefore, this model does not 
adequately explain the pathophysiology of drug-induced dyskinesias.  
 
 
Fig. 1. Classic rate model of the basal ganglia. Red – GABA (Inhibitory); Green – Glutamate 
(Excitatory); Blue – Degenerated Dopaminergic Nigrostriatal Pathway. Size of arrows 
indicate extent of activity. In the normal state, the “direct” and “indirect” pathways would 
appear the same as Fig. 1B, except that SNC is intact.  
4.2 Continuous versus pulsatile dopaminergic stimulation 
DA is constitutively available in the brain, specifically via the nigrostriatal pathway in the 
normal state. With loss of DA in PD, the brain no longer has constitutive availability of 
DA, thus DA receptors are no longer tonically stimulated. It has been proposed that 
chronic intermittent, pulsatile treatment with pharmacological DA replacement therapies 
such as LD or DA agonists leads to supersensitivity of dopaminergic receptors (Chase et 
al., 1989). After oral administration of pharmacological anti-PD medications, plasma 
levels of these therapies will fluctuate throughout the day based on pharmacokinetics and 
half-life of the drug in PD patients, thus providing intermittent activation of DA 
receptors. Presence of intact nigrostriatal neurons allows the brain to store, release and re-
uptake DA on demand. Since LD is a prodrug and has to be converted to DA, remaining 
intact nigrostriatal neurons are able to buffer, store, release on demand, and reuptake DA 
in early stages of PD. However, as the disease progresses to more advanced stages, there 
is extensive loss of nigrostriatal neurons and these mechanisms fail, leading to a more 
pulsatile activation of dopaminergic receptors. Drugs with longer half-lives, 
combinational pharmacological therapies and cell transplantation studies have provided 
evidence that continuous dopaminergic stimulation can both provide better symptomatic 
relief and mitigate/prevent drug-induced dyskinesias. Although there are groups 
working on biomarkers for drug-induced dyskinesias like positron emission tomography, 
there is no conclusive evidence that it can predict occurrence of dyskinesias (Feigin et al., 
2001; Eidelberg, 2009). 
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5. Biochemical and molecular mechanisms of drug-induced dyskinesias 
5.1 DA receptors 
DA receptors are metabotropic G-protein-coupled receptors widely expressed throughout 
the basal ganglia but mainly in the striatum. The two main family subtypes of DA receptors 
are D1-like and D2-like receptors. The pathophysiological mechanisms of drug-induced 
dyskinesias have been attributed to striatal DA receptor supersensitivity. Earlier studies 
have shown that the presence of mRNA encoding for D1 receptors decreases and D2 
receptors increases in response to dopaminergic denervation in earlier rodent studies 
(Gerfen et al., 1990), which is further confirmed in PD patients and MPTP-treated monkeys 
(Lee et al., 1978; Alexander et al., 1993; Morissette et al., 1996). More recently, Aubert et al. 
found differential changes of D1 and D2 receptor expression in dyskinetic monkeys, 
showing an increase in D2 mRNA and D2 ligand-binding compared to controls. D1 mRNA 
is also downregulated in MPTP monkeys but comparable to normal in LD treated 
parkinsonian monkeys. Further, they demonstrate that increased D1 receptor signaling is 
linearly related to dyskinesias (Aubert et al., 2005). It had been also been reported that there 
is an increase in both membrane and cytoplasmic striatal D1 receptor expression in MPTP-
treated dyskinetic monkeys compared to normal monkeys, with only moderate changes in 
D2 receptor expression (Guigoni et al., 2007).  
Therefore, previous studies demonstrate that plastic changes of DA receptors occur in 
response to DA denervation and pharmacological dopaminergic treatments. The notion of 
DA receptor supersensitivity is a combination of alterations to striatal DA receptor 
expression and subsequent G-protein second messenger signaling (see below). Although our 
understanding of DA receptor plasticity and supersensitivity has been studied mainly in the 
striatum for the underlying molecular changes associated with dyskinesias, future studies 
that examine alterations to the extrastriatal DA and receptor expression in the GPE, GPI, 
STN and SNR are warranted (Rommelfanger & Wichmann, 2010). 
5.2 Second messenger signals 
Neuronal second messenger signaling cascades are important for synaptic plasticity, 
modulation of downstream proteins and control of gene transcription factors (immediate 
early gene expression) which are modulated by DA receptors (Fig. 2). It has been reported 
that there is a significant increase of phosphorylation of ERK (P-ERK) in the DA denervated 
striatum in dyskinetic animals, and that blockade of ERK phosphorylation with the MEK1/2 
inhibitor SL-327 or Ras inhibitor lovastatin significantly decreases dyskinesias (Pavon et al., 
2006; Schuster et al., 2008; Ding et al., 2011). It has further been shown that phosphorylation 
of ERK increases in MSN after acute LD exposure but chronic LD exposure translates into a 
decrease in MSN ERK phosphorylation and reciprocal increases in cholinergic striatal 
interneurons. Similarly, another related second messenger signal, the DA- and cAMP-
regulated phosphoprotein of 32 kDa (DARPP-32) has also been implicated in the onset of 
drug-induced dyskinesias (Santini et al., 2010). More specifically, increased phosphorylation 
on the Thr34 (P-Thr34) site of the protein seems to be associated with onset of drug-induced 
dyskinesias (Guan et al., 2007). We have shown that striatal DARPP-32 expression is 
selectively decreased in dyskinetic hemiparkinsonian rats compared to normal rats (Lieu et 
al., 2008). In the normal rat, we found relative uniformity of DARPP-32 
immunohistochemical staining throughout the striatum bilaterally. However, in the LD-
treated dyskinetic rat, we found decreased staining in dorsolateral areas of the striatum in 
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the unlesioned hemisphere and an overall decrease in the density of staining in various 
regions of the lesioned hemisphere. Studies in dyskinetic rats and monkeys evaluating the 
transcription factors ∆FosB and ∆JunD within the striatum have also been implicated in the 
onset and maintenance of dyskinesias (Pavon et al., 2006; Berton et al., 2009; Cao et al., 2010). 
As mentioned previously, these maladaptive changes of second messenger signals are likely 
to be the direct result of DA receptor supersensitivity.  
 
 
Fig. 2. Signal transduction in drug-induced dyskinesias in Parkinson’s disease 
5.3 GABA 
GABA, being one of the major inhibitory neurotransmitters in the basal ganglia, is present in 
striatonigral and striatopallidal neurons. These 2 subsets of neurons express 2 isoforms of 
the GABA synthesizing enzymes, GAD65 and GAD67 (Mercugliano et al., 1992). Systematic 
administration of LD induces significant increases in GAD gene expression in striatonigral 
neurons (Soghomonian et al., 1996; Cenci et al., 1998; Carta et al., 2003; Nielsen & 
Soghomonian, 2004; Katz et al., 2005; Yamamoto & Soghomonian, 2009) and a small increase 
in GAD gene expression of striatopallidal neurons (Carta et al., 2003; Nielsen & 
Soghomonian, 2004; Carta et al., 2005). Although GABAergic striatal interneurons are not 
primarily affected in PD, as a result of progressive DA depletion, expression levels of GABA 
receptors change in the striatum. Subchronic administration of LD to 6-OHDA-lesioned rats 
induces marked increases in GABA release in the SNR (Yamamoto et al., 2006), and this 
increase was blocked by subchronic administration of an mGlutR5 agonist (Mela et al., 
2007). This suggests that a GlutR5 agonist can efficiently decrease the severity of drug-
induced dyskinesias in animal models of PD. Pulsatile dopaminergic stimulation can cause 
up-regulation of GABA receptors in GPI. GABA receptors were reported to be up-regulated 
in GPI of primates with drug-induced dyskinesias (Calon et al., 1999) and dyskinetic PD 
patients (Calon & Di Paolo, 2002). There have been reports on Modafinil preventing the 
MPTP-induced GABA-A receptor binding in the GPI of MPTP treated marmosets (Zeng et 
al., 2004). This study showed partial improvement in PD symptoms.  
5.4 Glutamate  
Glutamate is the main excitatory neurotransmitter in the basal ganglia. During the 
progression of PD, as a result of DA depletion in basal ganglia and treatment with LD or D1 
receptor agonists, the glutamate levels are elevated, and have shown that increased 
expression of glutamate receptor resulted in dyskinetic behavior (Calon et al., 2002; Ouattara 
et al., 2010). Calon and colleagues (Calon et al., 2002; Calon et al., 2003) have shown an 
elevation of NMDA receptor binding in the putamen (53%) during motor fluctuation when 
compared to patients without motor fluctuation. Later in support of Calon’s hypothesis, a 
number of ionotropic and metabotropic receptor antagonists have been shown to reduce 
drug-induced dyskinesias. A recent study showed a beneficial motor effect by AFQ056 (a 
metabotropic glutamate receptor type 5 antagonist) with LD in MPTP monkeys, supporting 
the therapeutic use of an mGluR5 antagonist to restore normal glutamatergic 
neurotransmission in PD and decrease dyskinesias (Gregoire et al., 2011).  
www.intechopen.com
 Pathophysiology of Drug-Induced Dyskinesias 
 
91 
5.5 Serotonin (5-HT) 
Carta et al. (Carta et al., 2007) showed a prodyskinetic effect by the DA released by 
serotonergic neurons. When they transplanted fetal serotonergic neurons into the DA 
denervated striatum, the dyskinetic behaviors were induced by a single dose of LD itself in 
an already primed animal when compared to the pretransplantation score. When fetal 
dopaminergic neuronal grafts were introduced, this was able to reduce the abnormal 
involuntary movements significantly. It was previously reported that the partial 5-HT1A 
agonist buspirone reduced development and expression of drug-induced dyskinesias 
(Eskow et al., 2007). Recently Politis and colleagues (Politis et al., 2010) showed that 
dyskinesias were markedly attenuated by systemic administration of a serotonin receptor 
agonist (5HT1AR agonist) which dampened the transmitter release from serotonergic 
neurons indicating that the dyskinesias were caused by the serotonergic hyperinnervation. 
i.e, serotonergic neurons mediate dyskinetic side effects in PD patients with normal 
transplants. Recently Zeng et al. observed that striatal 5-HT hyperinnervation follows 
nigrostriatal pathway loss and provide the first evidence in primates that chronic LD 
treatment and the onset of dyskinesias are associated with a marked hypertrophy of striatal 
5-HT axonal varicosities (Zeng et al., 2010). 
5.6 Acetylcholine 
Acetylcholine has been another neurotransmitter implicated in the modulation of drug-
induced dyskinesias. A number of studies have demonstrated that in 6-OHDA lesioned rats 
and MPTP dyskinetic monkeys, long term exposure to nicotine, which acts on nicotinic 
acetylcholine receptors, can reduce drug-induced dyskinesias. Interestingly, the nicotinic 
receptor antagonist mecamylamine can also provide similar effects (Quik et al., 2007; Bordia 
et al., 2008; Bordia et al., 2010). It has been recently demonstrated that drug-induced 
dyskinesias can effectively be decreased by selective nicotinic receptor agonists in dyskinetic 
partially lesioned rats (Huang et al., 2011). The authors suggest that expression of nicotinic 
receptors on dopaminergic terminals may play a role in modulating dyskinesias. As 
mentioned previously, studies have also demonstrated an increase in striatal cholinergic 
interneuron activity in dyskinetic mice (Ding et al., 2011). Thus, although acetylcholine is 
not as widely expressed as other neurotransmitters (glutamate, GABA, and DA) within the 
basal ganglia, its role in dyskinesias warrants further research. 
5.7 Adenosine 
Adenosine A2A receptors are G-protein-coupled receptors that have been implicated in the 
pathophysiology of drug-induced dyskinesias. Adenosone A2A receptors are mainly 
present in GABAergic striatopallidal neurons, colocalized with enkephalin and D2 
receptors. Adenosine A2A receptors mRNA levels in the putamen are known to be 
increased in PD patients with dyskinesias, when compared to normals or PD patients 
without dyskinesias. Furthermore, specific-binding to adenosine A2A receptors is elevated 
in dyskinetic PD patients compared to controls in the putamen, and elevated in PD patients 
when compared to normals in the GPE (Calon et al., 2004). These significant increases in 
A2A receptor mRNA have been further confirmed in the rat model of drug-induced 
dyskinesias when compared to sham-treated animals with LD treatment and 6-OHDA 
lesioned rats without LD (Tomiyama et al., 2004). Interestingly, increases in A2A receptor 
mRNA has been found in normal cynomolgus monkeys displaying dyskinesias with chronic 
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LD treatment (Zeng et al., 2000). Recently, it had been shown that genetic knock-out of 
forebrain A2A receptors in mice can attenuate dyskinesias after LD treatment (Xiao et al., 
2006). 
Adenosine A2A receptor antagonist administration in parkinsonism has been extensively 
examined, demonstrating that antagonism can increase anti-parkinsonian effects of 
pharmacological DA replacement therapies without exacerbating dyskinesias in preclinical 
models and in PD patients (Kanda et al., 1998; Lundblad et al., 2003; Xiao et al., 2006; LeWitt 
et al., 2008). Taken together, adenosine A2A receptor antagonists and pharmacological DA 
replacement treatment can be a useful combinational therapy to target dyskinesias. 
5.8 Other chemical systems 
Other chemical systems besides the traditional neurotransmitters are present throughout the 
basal ganglia and play an important role in dyskinesias. It has been shown that 
neuropeptide mRNA levels of striatal preproenkephalin (PPE) and preprodynorphin (PPD) 
are increased in dyskinetic MPTP-lesioned monkeys compared to control MPTP-lesioned 
monkeys, similar to previous reports in the 6-OHDA lesioned parkinsonian rat (Gerfen et 
al., 1990; Zeng et al., 2000; Morissette et al., 2006; Guan et al., 2007; Tamim et al., 2010).  
Using opioid receptor-stimulated G-protein activation techniques, Chen and colleagues 
demonstrated that µ-opioid receptor-mediated G-protein activation is increased in the brain, 
specifically the cortex and basal ganglia in dyskinetic monkeys treated with LD. They also 
found binding changes in δ- and κ-opioid receptor in these animals (Chen et al., 2005). 
Furthermore, µ-opioid and δ-opioid stimulated binding in the striatum was positively 
correlated to dyskinesia severity. In a later study, it was shown that pre-treatment with the 
κ-opioid agonist U50,488 can reduce drug-induced dyskinesias in the parkinsonian rat and 
primate (Cox et al., 2007). However, U50,488 had the deleterious effects of reducing the anti-
PD effects of LD.  
Another system is the cannabinoid system which is also widely expressed in the basal 
ganglia, and modulates the activity of other neurotransmitter systems such as glutamate 
and DA. Cao and colleagues demonstrate the selective antagonism of cannabinoid type 1 
receptor can increase the efficacy of LD without affecting the severity of dyskinesias in 
parkinsonian rhesus monkeys (Cao et al., 2007). Taken together, the biochemical and 
molecular mechanisms associated with dyskinesias are complex and still warrant further 
research. 
6. Electrophysiological changes in drug-induced dyskinesias 
6.1 Globus pallidus externa (GPE) and interna (GPI) 
Most of the present electrophysiological studies of drug-induced dyskinesias are linked to 
an excessive decrease in activity in the GPI. In a study by Filion et al. (Filion et al., 1991), the 
mixed (D1 and D2) DA agonist apomorphine was injected in MPTP monkeys. They showed 
that all GPI neurons decreased their firing rate following apomorphine. The reverse was 
true of the predominant neuronal population in the GPE. A similar study by Boraud et al. 
(Boraud et al., 1998) supports the correlation between dyskinesias and an excessive decrease 
in the firing frequency of GPI neurons. A similar excessive decrease was reported by Papa 
and colleagues (Papa et al., 1999) in MPTP-treated monkeys treated with LD. This study 
showed that during dyskinesias, the firing rates declined profoundly in almost all cells of 
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GPI, with a decrease as low as 97% in individual cells. From recordings in parkinsonian 
patients treated with apomorphine, Lozano and colleagues suggested that dopaminergic 
agents act by decreasing GPI and STN activity, and increasing GPE activity (Lozano et al., 
2000). They went on to suggest that drug-induced dyskinesias resulted from a large 
reduction in GPI firing. 
The predominant electrophysiological signature of drug-induced dyskinesias at present is 
the excessive decrease in GPI activity. However, the idea that the hypoactivity in GPI is the 
primary mechanism by which drug-induced dyskinesias occurs is challenged by the fact 
that a pallidotomy, which abolishes activity in GPI, eliminates dyskinesias (Baron et al., 
2000; Lozano et al., 2000). As a result, some have suggested that the pathophysiology of 
dyskinesias is not simply the result of the hypoactivity observed in GPI, but rather the result 
of a change in the firing pattern output of GPI. This would explain why a pallidotomy 
eliminates the drug-induced dyskinesias, as the abnormal firing pattern is removed (Obeso 
et al., 2002). 
Other studies have examined the role of oscillatory activity in the basal ganglia with respect 
to drug-induced dyskinesias. In MPTP monkeys, Heimer and colleagues (Heimer et al., 
2006) found increases in oscillatory activity and synchronization in GPI and GPE after 
induction of parkinsonism, and decreases in both following DA replacement therapy. 
Although DA replacement therapy had a reversal effect on the changes resulting from 
MPTP, they noted an imbalance in the oscillatory power and synchronization between GPI 
and GPE. Further studies on the electrophysiology of drug-induced dyskinesias must take 
into account the present results and explore the finer aspects of discharge characteristics like 
the firing patterns, multiple rhythms, oscillations, and synchronization in various regions of 
the basal ganglia circuitry. 
6.2 Subthalamic nucleus (STN) and substantia nigra reticulata (SNR) 
Since a change in the firing pattern of neurons from bursting to random pattern has also 
been implicated in the genesis of dyskinesias, recent work from our laboratory examined 
the effects of chronic LD treatments on the firing rate and firing pattern of STN and SNR 
neurons in the stable hemiparkinsonian monkey model of PD without dyskinesias 
(Gilmour et al., 2011). We also evaluated local field potentials (LFP) of both nuclei before 
and after LD treatments. We found that LD treatments did not significantly change the 
mean firing rate of STN neurons or bursting neuronal firing patterns. However, LD 
treatments induced a significant reduction of the mean firing rates of SNR neurons and a 
trend toward increased burstiness. The entropy of the spike sequences from STN and SNR 
was unchanged by LD treatment, but there was a shift of spectral power into higher 
frequency bands in LFP.  
In a recent study that recorded LFP from STN using an externalized deep brain stimulator 
electrode, a desynchronizing effect of LD was noticed on two separate rhythms of STN 
(Priori et al., 2004). The oscillatory activity increased at low frequency (2–7 Hz range), while 
the beta oscillations significantly decreased in the low-beta range. Similar effects were 
observed with apomorphine. Others have shown that an increase in the theta/alpha band of 
the oscillatory activity can lead to drug-induced dyskinesias in the presence of excess DA in 
the SNR of the 6-OHDA-lesioned rat (Meissner et al., 2006). These studies add to the 
evidence that the imbalance of multiple rhythm systems may lead to drug-induced 
dyskinesias.   
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Another recent study examined the activity changes in the SNR of non-parkinsonian 
monkeys with apomorphine induced orofacial dyskinesias (Nevet et al., 2004). Recordings 
were performed before (no dyskinesias) and after (with dyskinesias) administration of 
apomorphine. They found that 96% of the cells recorded exhibited a change in firing rate 
after the dose of apomorphine, with 70% showing a reduction. As in our study with LD, 
they did not observe significant changes in firing pattern. As a result, the authors suggest 
that dyskinesias are more related to a decrease in neuronal firing rate in the SNR, rather 
than a change in the firing pattern. More work is needed to understand the role of basal 
ganglia neuronal firing patterns and its relationship to the long-term symptomatic effects of 
LD treatment.  
6.3 Striatal medium-spiny neurons (MSN) 
Striatal MSN respond to DA input to the striatum, mediated by D1 (excitatory) and D2 
(inhibitory) DA receptors.  The “direct” striatal output pathway largely consists of the D1 
receptor type, whereas the “indirect” pathway consists of the D2 type. In a recent study, 
Liang and colleagues (Liang et al., 2008) recorded from MSN of severely parkinsonian 
monkeys during three periods: 1.) “OFF” states in which the monkeys exhibited 
parkinsonian disability; 2.) “ON” states in which the monkeys were treated with LD and 
regained motor control; and 3.) during high doses of LD which induced dyskinesias. During 
the OFF state, the authors found a significant increase in neuronal firing rate (2.7 – 52Hz), 
which is in contrast to what has been classically observed in the normal animal (0.5-2Hz). 
This increase in firing rate was observed in MSN from both the D1 and D2 pathway.  In the 
ON state, an overall increase in activity was observed, although some neurons exhibited an 
increase in firing rate (63.6%) and some a decrease (33.6%). It is assumed that the increases 
and decreases corresponded to the excitatory and inhibitory pathways, respectively. In the 
dyskinetic state, the overall firing rate was similar to that observed in the ON state. 
However, some neurons showed an increase in firing rate from OFF to ON to ON with 
dyskinesias, and some neurons showed an increase from OFF to ON and then a decrease 
during ON with dyskinesias. The authors suggest that this combination of uni- and 
bidirectional changes with increases in DA leads to an imbalance of MSN activity. 
Interestingly, this result correlates with the suggestion by others that although enabling 
movement, this imbalance of striatal activity may result in dyskinesias (Wichmann & 
DeLong, 1996; Mink, 2003). 
7. Graft-induced dyskinesias 
Cell grafts have been increasingly researched over the past three decades as a method of 
endogenously resupplying DA to the depleted basal ganglia in a continuous fashion. The 
primary type of cells used in the early studies was fetal ventral mesencephalic cells, 
progenitors to the nigral cells which degenerate in PD. In the 1990s and early 2000s, after 
animal studies and open-label clinical trials had shown therapeutic benefits of cell 
transplants, two double-blind placebo-controlled multicenter studies were funded by the 
National Institutes of Health (NIH).  
The results were disappointing; some patients received symptomatic benefits, but many 
patients did not (Freed et al., 2001; Olanow et al., 2003). Additionally, up to half of the 
patients developed dyskinetic movements that persisted even after multi-day withdrawal of 
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dopaminergic medications. These symptoms have since been labeled graft-induced 
dyskinesias (GID) and look similar to diphasic dyskinesias. Several hypotheses have been 
proposed for the cause of these GID. 
One of the first proposed causes of GID was that the grafts were producing "hotspots" of 
excessive DA in small, localized areas of the striatum. A related factor of dorsal versus 
ventral striatal placement was suspected. It was suggested that small DA-producing grafts 
might be reducing the striatal DA supersensitivity only in a small area around each graft, 
and this imbalanced and patchy reinnervation produced GID. In support of this hypothesis, 
Ma and colleagues (Ma et al., 2002) saw significantly increased uptake of 18F-dopa in five 
patients with GID, with the increase localized to small focal areas in the grafted putamen. 
This hypothesis was also supported by a study by Carlsson and colleagues in a rat model of 
PD showing differential effects on drug-induced dyskinesias due to rostral versus caudal 
striatal grafts (Carlsson et al., 2006). However, Piccini and colleagues showed using another 
18F-dopa experiment that patients with GID did not show abnormal DA release from graft 
areas (Piccini et al., 2005), and subsequent post-hoc analysis of larger numbers of grafted 
patients showed no correlation between striatal reinnervation and GID (Hagell et al., 2002; 
Olanow et al., 2003). 
Another hypothesis was that GID were caused by immune system rejection of the grafts. 
Early analyses showed that some patients with GID showed low-level inflammation around 
their grafts (Hagell et al., 2002), and GID worsened in some patients after 
immunosuppression was stopped (Piccini et al., 2005). However, a recent experiment which 
induced graft rejection in a rat model did not show an increase in abnormal involuntary 
movements, suggesting that inflammation and rejection alone may not be the primary cause 
of GID (Lane et al., 2008). 
Because the risk of developing GID has been shown to vary depending on the patient, 
another hypothesis for the origin of GID is that it stems from the same pathophysiology as 
drug-induced dyskinesias. All of the original patients in the Freed and Olanow NIH studies 
who developed GID had previously been exposed to many years of intermittent LD therapy, 
suggesting possible priming and hypersensitization of the striatum. Pre-transplant drug-
induced dyskinesias has been implicated in the development of GID and is increasingly seen 
as a counterindication for transplant (Lane et al., 2010). Experiments in rodent PD models 
have similarly shown correlations between pre-transplant drug-induced dyskinesias and 
post-transplant amphetamine-induced dyskinesias (Lane et al., 2006; Lane et al., 2009; Lane 
et al., 2009). 
Another hypothesis is that GID is the result of aberrant synaptic graft-host connectivity. 
Studies have previously shown degeneration of dendrites and dendritic spines on the 
striatal MSN in advanced PD (Stephens et al., 2005). Soderstrom and colleagues recently 
looked at synaptic connections to dendrites near graft sites, showing that decreases in 
tyrosine hydroxylase-positive synapses onto striatal dendritic spines and increases in 
asymmetric excitatory synapses correlate with GID in rat models (Soderstrom et al., 2008). 
Further studies showed that chronic administration of nimodipine, a calcium channel 
blocker which had been shown to preserve striatal dendritic spines, reduced GID 
(Soderstrom et al., 2010). Another approach to avoiding aberrant graft synaptic connectivity 
has been the use of retinal pigment epithelial (RPE) cells, which produce LD and possibly 
DA but do not form axons or synaptic connections (Subramanian et al., 2002; Bakay et al., 
2004). These RPE cells have been shown to provide symptomatic benefit in both animal 
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trials and open-label clinical studies. Promising recent research with new inducible 
pluripotent stem cells and inducible neuron-like cells shows progress toward dopaminergic 
therapeutic grafts developed from patients’ own donor cells (Wernig et al., 2008; Vierbuchen 
et al., 2010).  
A final hypothesis for the cause of GID is the accidental inclusion of serotonergic cells in the 
dopaminergic graft. Serotonergic neurons are known to be able to convert, store, and release 
DA under certain conditions (Tanaka et al., 1999). The patients in the Freed NIH study who 
developed GID had been transplanted with neurons which had been cultured for several days, 
a technique which is known to increase the proportion of serotonergic neurons compared to 
dopaminergic neurons. It was recently shown in a rat PD model that serotonergic striatal 
grafts increased drug-induced dyskinesia activity (Carta et al., 2007; Carlsson et al., 2009). 
Drug-induced dyskinesias is not identical to GID, as drug-induced dyskinesias is seen during 
and after the surge in DA which follows LD ingestion (de la Fuente-Fernandez et al., 2004), 
and some studies show no relationship between GID and serotonergic innervation in the rat 
model (Lane et al., 2009). However, recent studies in human patients continue to support the 
serotonergic cograft hypothesis for GID. Politis and colleagues used 11C-DASB PET to show 
that two grafted patients with GID showed much higher levels of striatal serotonin receptor 
expression than other grafted patients without GID (Politis et al., 2010). Furthermore, GID was 
significantly reduced by systemic administration of buspirone, a 5-hydroxytryptamine agonist 
which reduces serotonin release. 
In summary, the exact cause of GID still remains to be clarified, and several factors may well 
be involved. Promising hypotheses for reducing GID are garnering increasing experimental 
support, including selection of patients without severe drug-induced dyskinesias, 
optimization of novel cell sources and transplant techniques to reduce immune reaction and 
decrease serotonergic progenitor cells, and pharmacological methods of preserving striatal 
spines and increasing striatal dopaminergic reinnervation. 
8. Adjunct drugs to reduce drug-induced dyskinesias 
8.1 Amantadine  
Amantadine is a NMDA receptor antagonist and has been found to be efficacious in the 
treatment of drug-induced dyskinesias without reducing antiparkinsonian benefits. Its 
antidyskinetic effect gives support to the glutamatergic theory as a pathophysiological 
mechanism. Double-blind placebo-controlled studies have demonstrated 45% to 60% 
reductions in dyskinesia. Benefits are typically seen in 3 weeks following initiation of 
treatment. The benefits of Amantadine have been shown to last for only 8 months to 1 year 
in some studies (Sawada et al., 2010). A more recent study has shown that the antidyskinetic 
effects last longer than 1 year and has advocated the continued use of Amantadine for the 
treatment of dyskinesias (Wolf et al., 2010). Also, discontinuation of Amantadine has been 
shown to worsen dyskinesias. Amantadine is initiated at a dose of 100 mg/day and can be 
increased up to 300 mg/day. Potential side effects are confusion, hallucination, edema of 
feet and livedo reticularis.  
8.2 Sarizotan  
Sarizotan is a 5-HT1A receptor agonist and is a high affinity antagonist for D3 and D4 
receptors. The beneficial effects of Sarizotan are probably due to its 5-HT1A agonist 
www.intechopen.com
 Pathophysiology of Drug-Induced Dyskinesias 
 
97 
properties. It has been found to reduce dyskinesia in 6-OHDA lesioned rats and in MPTP-
lesioned monkeys (Bibbiani et al., 2001). In open label studies, Sarizotan in a dose range of 4 
to 20 mg/day showed promising results in decreasing dyskinesias (Olanow et al., 2004). A 
double-blinded placebo-controlled study demonstrated significant decrease in the duration 
and severity of dyskinesias on the Unified Parkinson’s Disease Rating Scale (UPDRS) with 2 
mg/day Sarizotan compared to placebo. UPDRS is a standard rating tool used in clinical 
research. Other clinical tools to measure dyskinesias (patients' home diary and abnormal 
involuntary movements scale score) did not show any changes while on this dose. Higher 
doses were associated with worsening of parkinsonism with no additional anti-dyskinetic 
benefits (Goetz et al., 2007). Sarizotan is well-tolerated and studies have not shown any 
adverse effect compared to placebo. 
8.3 Levetiracetam  
Levetiracetam is an anti-epileptic drug. It has been found to reduce dyskinesias in MPTP 
lesioned primates. We were the first to report improvement in drug-induced dyskinesias 
upon treatment with low doses of Levetiracetam in an open label study (Tousi & 
Subramanian, 2005). Other open label studies provided mixed efficacy results and poor 
tolerability due to somnolence. More recently, two double-blinded placebo-controlled 
studies have evaluated the efficacy and safety of Levetiracetam in the treatment of 
dyskinesias (Stathis et al., 2010; Wolz et al., 2010). In one study (Wolz et al., 2010), patients 
received 250 mg/day titrated gradually to a dose of 2000 mg/day over 7 weeks followed by 
a 4-week maintenance phase. There was a significant difference in UPDRS dyskinesia 
ratings (duration and severity) between the two groups. There was no significant change in 
abnormal involuntary movements scale score. In the other study (Stathis et al., 2010), 
patients received 500 mg/day and 1000 mg/day each for 2 weeks. ‘On with dyskinesia’ time 
decreased and ‘On without dyskinesia’ time increased significantly in the treatment group. 
Duration of dyskinesias decreased significantly while, severity decreased but the change 
was not significant. Both studies did not demonstrate worsening of parkinsonian symptoms. 
The most common side effects are somnolence and dizziness. However, in contrast to the 
open label studies that reported intolerable side effects leading to high dropout rates, the 
double-blinded placebo-controlled studies did not report severe adverse effects. The 
mechanisms of the antidyskinetic effects of Levetiracetam are unknown. It has been 
hypothesized that it could be due to modulation of the pathological synchronization and 
desynchronization of neuronal circuits of the basal ganglia and maladaptive DA release and 
reuptake at the presynaptic level. The recent trials provide promising data that 
Levetiracetam might be useful for treatment of drug-induced dyskinesias without reducing 
the efficacy of antiparkinsonian therapy. 
8.4 DA agonists  
DA agonists are often used as adjuncts to LD in advanced PD. DA agonists exert their 
pharmacological effect by directly activating the DA receptors bypassing the presynaptic 
synthesis of DA. These include non-ergot compounds, such as Ropinirole and Pramipexole, 
and apomorphine. DA agonists when used as the initial form of therapy can help to delay 
onset of LD-induced complications. In patients who have already developed dyskinesias, 
addition of a DA agonist may permit a reduction in LD dose without worsening of 
parkinsonism. The addition of a DA agonist might result in worsening of dyskinesias but this 
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can be corrected by lowering the dose of LD. If lowering the dose of LD results in increased 
“off” states, then the agonist dose needs to be increased. However, patients experiencing 
severe dyskinesias are rarely controlled with this regimen in the long term. Apomorphine 
being water-soluble can be injected subcutaneously or applied intranasally. The use of 
continuous subcutaneous apomorphine infusion has been found to abort “off” periods, reduce 
dyskinesias, and improve PD motor scores, with the added benefit of an LD-sparing effect 
(Deleu et al., 2004). Apomorphine can cause severe nausea and vomiting due to its fast onset of 
action. Hence the patient should be pretreated to prevent nausea. Ropinirole and Pramipexole 
are initiated at a dose of 0.25 mg and 0.125 mg three times a day respectively and titrated to 
effect (Hinson, 2010). In contrast to the traditional ergot agonists, the non-ergots have a lower 
risk of complications such as peptic ulcer disease, vasoconstrictive effects, erythromelalgia and 
valvular heart disease. Other common adverse effects include drowsiness, sleep attacks, 
confusion, orthostatic hypotension, nausea and leg/ankle edema. Ropinirole has a higher 
incidence of hypotension and somnolence while Pramipexole is associated with a higher risk 
of hallucinations (Jankovic & Aguilar, 2008). 
9. Surgical management of drug-induced dyskinesias 
Drug-induced dyskinesias have a treatment limiting effect on pharmacological approaches 
in the treatment of PD. In these patients, surgical intervention becomes necessary. Ablative 
surgeries in the past had a relatively limited role due to the nature of the procedure, 
irreversibility and the inability to modulate the therapy according to the need of the patient. 
Since the advent of deep brain stimulation (DBS), surgical options have become more 
accepted in these patients (Rezai et al., 2008). Both ablative and DBS procedures are effective 
in the treatment of LD-induced motor complications, such as drug-induced dyskinesias, that 
cannot be satisfactorily controlled with medical therapies (Guridi et al., 2008). The 
modalities by which surgical interventions reduce dyskinesias are multifold: 1) Reduction in 
daily DA intake; 2) Increasing on-time and thus reducing the repetitive LD dosing 
schedules; 3) Direct anti-dyskinesia effect. 
9.1 Ablative procedures 
Ablative procedures effective in controlling drug-induced dyskinesias include: 
9.1.1 Thalamotomy 
The anti-dyskinesia effect of thalamotomy has been variable. Ventral intermedius nucleus 
(VIM) of thalamus is not a part of the pallidal receiving area and hence does not have an 
anti-dyskinesia effect (Tasker et al., 1997). A lesion in the pallidal receiving area of thalamus 
(nucleus ventralis oralis and ventralis posterior VoA and VoP) has been shown to have 
profound anti-dyskinesia effects (Narabayashi et al., 1984). In a study of thalamotomy in 
MPTP monkeys, Page et al. found that a lesion of the pallidal outflow receiving areas of the 
thalamus had a significant anti-dyskinesia effect but similar lesions in cerebellar or nigral 
outflow receiving areas (VIM) had no anti-dyskinesia effect (Page, 1992; Page et al., 1993).  
9.1.2 Pallidotomy  
Posteroventral pallidotomy has been shown to have a significant and sustained anti-
dyskinesia effect (Lozano et al., 1995; Baron et al., 1996). A randomized, controlled trial by 
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Vitek et al. (Vitek et al., 2003) comparing unilateral pallidotomy with medical therapy 
showed improvement in contralateral dyskinesias in all patients with a significant reduction 
in ipsilateral dyskinesias. Several other studies have confirmed the significant and sustained 
anti-dyskinesia effect of pallidotomy (de Bie et al., 1999; Merello et al., 1999). The 
mechanism of action of pallidotomy in reducing drug-induced dyskinesias is more complex. 
Pallidotomy improves PD symptoms by reducing pallidal neuronal activity, which in turn 
restores thalamocortical excitability. This should theoretically worsen the drug-induced 
dyskinesias.  The anti-dyskinetic effect of pallidotomy is considered the function of 
normalizing the pattern of firing of GPI (Guridi et al., 2008). The optimal lesion location 
within the GPI has been variously argued to be anteromedial (Gross et al., 1999) and 
posteroventral (Krauss et al., 1997).  
9.1.3 Subthalamotomy 
Subthalamotomy is performed in a small number of patients due to the risk involved in the 
procedure. Alvarez et al. (Alvarez et al., 2001) reported no anti-dyskinesia effect of unilateral 
subthalamotomy in the short-term or long-term (Alvarez et al., 2009) follow-up. Around 
15% of patients (14 patients) with unilateral subthalamotomy in this study developed 
postoperative hemichorea-ballism which required an additional pallidotomy in eight 
patients (Alvarez et al., 2009). On the other hand, Su et al. (Su et al., 2003) reported a 
significant reduction (75%) in dyskinesias after unilateral subthalamotomy in their study. 
They also state that the lesions in patients with anti-dyskinesia effect were larger and 
probably affected the pallidofugal fibers. With a significant risk of developing postoperative 
hemichorea-ballism and variable anti-dyskinetic response, subthalamotomy is probably the 
least useful procedure for treating dyskinesias.  
All of these ablative procedures are associated with an increased risk of hemorrhage and 
bilateral ablative procedures are associated with further risks, including speech, 
swallowing, and cognitive problems. With the advent of DBS, ablative lesions are now 
rarely performed.  
9.2 Deep Brain Stimulation 
DBS for PD is routinely performed on patients with medically intractable PD.  The targets 
for DBS in PD have included a number of nodal points in the basal ganglia thalamocortical 
circuit.  These include the VIM of the thalamus, the GPI and the STN (Rezai et al., 2008). 
VIM DBS predominately improves tremor; GPI and STN have been the primary targets for 
the treatment of the motor symptoms associated with PD. Though GPI and STN DBS both 
improve PD symptoms (e.g., tremor, rigidity and bradykinesia), there is a continued debate 
over which site is more effective in improving motor symptoms, reducing PD medications 
and controlling medication associated side effects such as drug-induced dyskinesias and 
motor fluctuations (Krack et al., 1998; Burchiel et al., 1999; Limousin-Dowsey et al., 1999; 
Allert et al., 2001; Krause et al., 2001; Volkmann, 2004; Anderson et al., 2005). Another area 
of interest is stimulation of the pedunculopontine nucleus (PPN) for PD. 
9.2.1 VIM DBS  
VIM DBS provides excellent tremor relief, but does not have anti-dyskinesia effect, as shown 
in various studies (Benabid et al., 1996; Tasker et al., 1996; Limousin-Dowsey et al., 1999). 
However, some anti-dyskinesia effect is observed in VIM DBS when the electrode is more 
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posterior, medial, and deeper, probably modulating the centromedian and parafascicular 
complex (Caparros-Lefebvre et al., 1993).  
9.2.2 GPI DBS 
Most major studies have reported that GPI DBS is effective in reducing all the cardinal motor 
signs of PD as well as improving motor fluctuations, reducing dyskinesias and increasing on 
time (The Deep-Brain Stimulation for Parkinson's Disease Study Group, 2001). Ghika et al. 
(Ghika et al., 1998) reported that the mean off time decreased from 40% to 10%, and the mean 
dyskinesia scores were reduced to one-third. Burchiel et al. reported a significant reduction in 
dyskinesias (Burchiel et al., 1999), while Kumar et al. reported that the reduction in the total 
"on" dyskinesias score was 66% (Kumar et al., 2000). Volkmann et al. reported a sustained 
reduction in dyskinesias at 5 years follow up of 64% (Volkmann et al., 2004). Rodrigues et al. 
reported a reduction in dyskinesia scores by 76% (Rodrigues et al., 2007) out 4 years. Several 
such studies have confirmed that pallidal stimulation is associated with a marked reduction in 
contralateral drug-induced dyskinesias in addition to improvements in “off”-period. The 
duration of benefit on motor complications following DBS-GPI is sustained. The location of the 
DBS lead has an effect on the anti-dyskinetic effect of GPI DBS. Bejjani et al. (Bejjani et al., 1997; 
Bejjani et al., 1998) have demonstrated different clinical effects after stimulation of the dorsal 
and the posteroventral part of the GP. With stimulation in the more dorsal portions of the 
pallidum, they reported improvement in akinesia and rigidity, but an exacerbation of 
dyskinesias. Stimulation in the posteroventral portion of the GP had a pronounced anti-
dyskinetic effect, but worsened bradykinesia. 
9.2.3 STN DBS 
STN DBS has been the established modality of therapy for advanced PD patients since the 
initial studies by the group of Dr. Benabid in Grenoble. STN DBS has shown a dramatic and 
sustained anti-dyskinesia effect in various major studies (Limousin et al., 1995; Krack et al., 
1997; Limousin et al., 1998; Benabid et al., 2000). The effect of STN DBS on drug-induced 
dyskinesias is homogeneous and well accepted. Patients undergoing STN DBS have a 
significant antidyskinetic effect that can be closely correlated with a reduction in LD dose 
(Guridi et al., 2008). STN DBS improves peak-dose as well as biphasic dyskinesia (Krack et 
al., 1997). It also results in significant reduction (47%) in LD dose (Krack et al., 1997). The 
reduction in dose and drug-induced dyskinesias is sustained over a long period. In a survey 
published by Hamani et al. of multiple studies involving 737 patients in 34 neurosurgery 
units, STN DBS improved drug-induced dyskinesias by 73% at 6 months and 94% at 12 
months in the on-stimulation on-medication state in comparison to the preoperative on-
medication scores (Hamani et al., 2005). Long-term studies of bilateral DBS-STN in patients 
with advanced PD demonstrate the stability of this therapeutic efficacy.  
9.2.4 PPN DBS 
PPN DBS has been used in a number of PD patients for gait and postural impairment (Tsang 
et al., 2010). Early studies suggested that PPN DBS could be utilized in patients who 
respond poorly to anti-PD medications or other neurosurgical treatments (Plaha & Gill, 
2005). This was later confirmed in patients receiving both PPN and STN DBS (Stefani et al., 
2007). Although the authors suggest that this procedure is appropriate for treating 
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parkinsonian symptoms, they indicate that  PPN DBS is not suitable in targeting drug-
induced dyskinesias. In 2010, Ferraye and colleagues found that PPN DBS only provided 
modest amelioration of parkinsonian symptoms. According to their findings, dyskinesias 
were not alleviated with PPN stimulation (Ferraye et al., 2010). 
9.2.5 DBS Conclusion 
It is evident that DBS is an effective therapy for PD patients with motor complications like drug-
induced dyskinesias. The primary benefit of DBS is on dyskinesia and “off” time. Stimulation of 
both the GPI and the STN are effective in treating the motor features of PD and LD related 
motor complications like drug-induced dyskinesias, but the preferable target remains a 
controversial topic. It is possible that stimulation of the GPI has a more direct effect in blocking 
dyskinesias, while reduction in dyskinesias with STN DBS may primarily relate to a reduction 
in LD dose. A recent study compared the effects of STN DBS and GPI DBS (Follett et al., 2010). 
Subthalamic and pallidal DBS resulted in improvement in motor function, reduction in 
dyskinesias and reduction in dose of dopaminergic medications. Effects on motor function and 
dyskinesias did not differ significantly between the two groups. Patients undergoing 
subthalamic stimulation required a significantly lower dose of dopaminergic agents than did 
those undergoing pallidal stimulation. The difference may be an important consideration in 
patients having side effects, as a reduction in medications may lead to a better quality of life. 
10. Key points for the pathophysiology of drug-induced dyskinesias 
• The classic rate model of the basal ganglia does not completely explain drug-induced 
dyskinesias. 
• Despite numerous advances in understanding the changes to neurochemical sub-
systems in the striatum and downstream nuclei in the basal ganglia in dyskinesias, the 
prevailing hypothesis of D1 and D2 receptor supersensitivity due to loss of continuous 
dopaminergic stimulation is still the unifying conceptual idea for drug-induced 
dyskinesias. However, this idea still does not entirely explain the phenomenology of 
drug-induced dyskinesias. 
• Alternate theories for drug-induced dyskinesias include: basal ganglia neuronal firing 
pattern abnormalities, interhemispheric inhibition, and alterations to second messenger 
systems as complementary pathophysiological mechanisms. 
• Despite significant advances in the field, treatment for drug-induced dyskinesias in PD 
is largely unsatisfactory for many patients. 
• We have made excellent advances in clinical distinction of drug-induced dyskinesias 
from other syndromes. 
• Many new treatments are currently being examined, and understanding the 
pathophysiological basis of drug-induced dyskinesias will allow for better development 
of these novel therapies. 
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